Free biotech catalyst calendar
Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.
250 programs as of
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
These records could not be loaded. Open a numbered page to read the original quotations and SEC links.
Months the companies stated
11 days left
in Hamburg, Germany, October 27-30, 2026.Details
Benitec Biopharma Inc. (BNTC) · BB-301
Stage: OtherSEC filing · “Phase 1b/2a”
Public float (as of ): $143M (SEC filing) · Under $500M
Month the company stated:
Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026.
ClinicalTrials.gov NCT06185673 · NCT stated in SEC filing
Earlier SEC statements (1)
- · “Benitec remains on track to provide updated interim clinical study results for Cohort 1 patients and Cohort 2 patients in 2H-2026.” · SEC filing
12 days left
being presented at ESMO in October 2026Details
Biohaven Ltd. (BHVN) · BHV-1530
Stage: Not stated
Public float (as of ): $1.0B (SEC filing) · $500M–$2B
Month the company stated:
New clinical data with BHV-1530, an FGFR3-directed ADC using a novel TopoIx payload, being presented at ESMO in October 2026
12 days left
results are expected in October 2026.Details
Rapport Therapeutics, Inc. (RAPP) · RAP-219 · bipolar mania
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $275M (SEC filing) · Under $500M
Month the company stated:
topline results are expected in October 2026.
Earlier SEC statements (3)
- · “topline results are now expected in the fourth quarter of 2026” · SEC filing
- · “topline results are now expected in the fourth quarter of 2026” · SEC filing
- · “RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026” · SEC filing
21 days left
2026, taking place November 6-9, 2026, in Chicago, Illinois.Details
Editas Medicine, Inc. (EDIT) · EDIT-401
Stage: OtherSEC filing · “preclinical”
Public float (as of ): $191M (SEC filing) · Under $500M
Month the company stated:
The Company also announced that new preclinical data, demonstrating durability of LDL-C reduction with EDIT-401, will be released via an oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.
29 days left
2026, to be held November 14 – 17, 2026.Details
Corbus Pharmaceuticals Holdings, Inc. (CRBP) · CRB-913
Stage: Phase 1SEC filing · “Phase 1b”
Public float (as of ): $67M (SEC filing) · Under $500M
Month the company stated:
will be detailed in a late-breaking presentation at ObesityWeek® 2026, to be held November 14 – 17, 2026.
ClinicalTrials.gov NCT07310901 · NCT stated in SEC filing
31 days left
conference, taking place November 16-19, 2026 in Boston.Details
ACADIA PHARMACEUTICALS INC (ACAD) · remlifanserin
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $2.3B (SEC filing) · Over $2B
Month the company stated:
The Company plans to present detailed safety and efficacy results from the RADIANT Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16-19, 2026 in Boston.
42 days left
Rheumatology Convergence 2026 in November.Details
Cullinan Therapeutics, Inc. (CGEM) · velinotamig
Stage: Not stated
Public float (as of ): $442M (SEC filing) · Under $500M
Month the company stated:
in a poster session at American College of Rheumatology Convergence 2026 in November.
SEC timing context:
On September 24, 2026, the Company outlined its plans to share the following immunology and oncology pipeline updates in the fourth quarter of 2026.
Earlier SEC statements (3)
- · “Additional multi-dose regimen data from the trial are expected to be shared in the fourth quarter of 2026.” · SEC filing
- · “Additional multi-dose regimen data from the study are expected to be shared in Q4 2026.” · SEC filing
- · “Additional multi-dose regimen data in patients with SLE” · SEC filing
- REGNRegeneron Pharmaceuticals · cemdisiran · generalized myasthenia gravisPDUFA target date (company stated) MatchedSEC ↗Watch
42 days left
a target action date in November 2026, following use of a Priority Review Voucher.Details
REGENERON PHARMACEUTICALS, INC. (REGN) · cemdisiran · generalized myasthenia gravis
Stage: PDUFASEC filing · “target action date”
Public float (as of ): $54.8B (SEC filing) · Over $2B
Month the company stated:
The FDA will review the New Drug Application (NDA) under priority review with a target action date in November 2026, following use of a Priority Review Voucher.
73 days left
in the fourth quarter of 2026.Details
Cullinan Therapeutics, Inc. (CGEM) · CLN-049
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $442M (SEC filing) · Under $500M
Month the company stated:
The Company plans to share updated data from the dose escalation portion of its ongoing Phase 1 trial of CLN-049 in patients with relapsed/refractory acute myeloid leukemia in December.
SEC timing context:
On September 24, 2026, the Company outlined its plans to share the following immunology and oncology pipeline updates in the fourth quarter of 2026.
73 days left
in the fourth quarter of 2026.Details
Cullinan Therapeutics, Inc. (CGEM) · CLN-978
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $442M (SEC filing) · Under $500M
Month the company stated:
The Company plans to share both multi-dose and single target dose regimen data from each of its ongoing Phase 1 clinical trials of CLN-978 in patients with (i) treatment-refractory moderate to severe systemic lupus erythematosus ("SLE"), (ii) difficult-to-treat rheumatoid arthritis ("RA") and (iii) treatment-refractory moderate to severe Sjögren's disease in December.
SEC timing context:
On September 24, 2026, the Company outlined its plans to share the following immunology and oncology pipeline updates in the fourth quarter of 2026.
Earlier SEC statements (1)
- · “• OUTRACE SjD o In Q4 2026, the Company plans to share initial data from the single target dose escalation portion of the study.” · SEC filing
Window ends in: Q4 2026
Grouped by the period end. The company's wording is retained in each row; no countdown is shown.
Period the company stated: September to November 2026
now anticipated in the September to November 2026Details
ACADIA PHARMACEUTICALS INC (ACAD) · trofinetide
Stage: Not stated
Public float (as of ): $2.3B (SEC filing) · Over $2B
Period the company stated: September to November 2026
trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026
Period the company stated: Q4 2026
data readout expected in Q4 2026.Details
AbCellera Biologics Inc. (ABCL) · ABCL575
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $789M (SEC filing) · $500M–$2B
Period the company stated: Q4 2026
Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.
ClinicalTrials.gov NCT07108894 · matched by ORION (not stated in the filing)
Matching evidence
- Sponsor
- Filing issuer: AbCellera Biologics Inc. · Registry: AbCellera Biologics Inc.
- Medicine
- Filing: ABCL575 · Registry: ABCL575
- Phase
- Filing: Phase 1 · Registry: Phase 1
Registration title: A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Registry observed:
ClinicalTrials.gov: “A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants”
Earlier SEC statements (1)
- · “We anticipate the topline data readout for the Phase 1 study in Q4 2026.” · SEC filing
Period the company stated: fourth quarter of 2026
commercial supply in the fourth quarter of 2026Details
ACHIEVE LIFE SCIENCES, INC. (ACHV) · cytisinicline
Stage: Not stated
Public float (as of ): $103M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
The Company intends to resubmit its NDA naming Adare as its finished drug product manufacturer for commercial supply in the fourth quarter of 2026
Earlier SEC statements (1)
- · “The Company intends to resubmit its New Drug Application in the fourth quarter of 2026, naming Adare as its new and primary manufacturing partner for commercial supply.” · SEC filing
Period the company stated: 4Q 2026
plaque psoriasis in 4Q 2026Details
ALUMIS INC. (ALMS) · envudeucitinib
Stage: Not stated
Public float (as of ): $183M (SEC filing) · Under $500M
Period the company stated: 4Q 2026
Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026
Earlier SEC statements (3)
- · “we plan to submit an NDA for envu for PsO in the fourth quarter of 2026” · SEC filing
- · “we plan to submit an NDA for envu for PsO in the second half of 2026” · SEC filing
- · “we plan to submit an NDA for envu for PsO in the second half of 2026” · SEC filing
Period the company stated: Q4 2026
Data expected in Q4 2026Details
ANAPTYSBIO, INC (ANAB) · dostarlimab
Stage: Not stated
Public float (as of ): $432M (SEC filing) · Under $500M
Period the company stated: Q4 2026
Data expected in Q4 2026
Period the company stated: fourth quarter of 2026
FORWARD trial expected in fourth quarter of 2026.Details
Annexon, Inc. (ANNX) · tanruprubart
Stage: Not stated
Public float (as of ): $244M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.
Earlier SEC statements (1)
- · “Next Milestone: BLA submission with initial U.S./European data from FORWARD trial anticipated in 2026.” · SEC filing
Period the company stated: fourth quarter of 2026
remains on track for the fourth quarter of 2026.Details
Annexon, Inc. (ANNX) · vonaprument
Stage: Not stated
Public float (as of ): $244M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
The Month 15 primary endpoint remains on track for the fourth quarter of 2026.
Earlier SEC statements (1)
- · “Next Milestone: Topline Phase 3 ARCHER II trial data expected in fourth quarter of 2026.” · SEC filing
Period the company stated: fourth quarter of 2026
a medical meeting in the fourth quarter of 2026.Details
Aprea Therapeutics, Inc. (APRE) · APR-1051
Stage: Not stated
Public float (as of ): $8M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
We expect to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.
Period the company stated: fourth quarter of 2026
study (MMN) expected in fourth quarter of 2026Details
ARGENX SE (ARGX) · empasiprubart
Stage: Not stated
Public float: Unknown (no public float found in SEC filings)
Period the company stated: fourth quarter of 2026
Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026
Period the company stated: Q4 of 2026
advancement anticipated in Q4 of 2026Details
Arcutis Biotherapeutics, Inc. (ARQT) · roflumilast foam 0.3%
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $1.5B (SEC filing) · $500M–$2B
Period the company stated: Q4 of 2026
Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo with disclosure of topline results and decision on program advancement anticipated in Q4 of 2026
Period the company stated: fourth quarter of 2026
Movement Disorders in the fourth quarter of 2026Details
ARVINAS, INC. (ARVN) · ARV-102
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $469M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
additional biomarker data from the Phase 1 clinical trial in patients with PD at the International Congress on Parkinson’s Disease and Movement Disorders in the fourth quarter of 2026
Earlier SEC statements (1)
- · “additional biomarker data from the Phase 1 clinical trial in patients with PD in the second half of 2026” · SEC filing
Period the company stated: 4Q26
line data anticipated in 4Q26Details
ATOSSA THERAPEUTICS, INC. (ATOS) · (Z)-endoxifen + abemaciclib
Stage: Not stated
Public float (as of ): $107M (SEC filing) · Under $500M
Period the company stated: 4Q26
Enrollment completed, top line data anticipated in 4Q26
Earlier SEC statements (2)
- · “we expect to begin receiving data early in the second half of 2026.” · SEC filing
- · “we expect to begin receiving data in the second half of 2026.” · SEC filing
Period the company stated: 4Q 2026
in binge eating disorder (4Q 2026)Details
Axsome Therapeutics, Inc. (AXSM) · solriamfetol
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $4.4B (SEC filing) · Over $2B
Period the company stated: 4Q 2026
Clinical Trial Topline Results: o Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (4Q 2026)
Period the company stated: fourth quarter of 2026
besadenovec in the fourth quarter of 2026Details
Candel Therapeutics, Inc. (CADL) · aglatimagene besadenovec
Stage: Not stated
Public float (as of ): $245M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
planned submission of the BLA for aglatimagene besadenovec in the fourth quarter of 2026
Earlier SEC statements (4)
- · “The campaign is progressing well and is a critical CMC activity to enable the anticipated BLA submission in Q4 2026.” · SEC filing
- · “anticipated submission of a Biologics License Application for CAN-2409 in prostate cancer in the fourth quarter of 2026.” · SEC filing
- · “we anticipate submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.” · SEC filing
- · “we anticipate submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.” · SEC filing
Period the company stated: fourth quarter of 2026
long-term survivors in the fourth quarter of 2026.Details
Candel Therapeutics, Inc. (CADL) · linoserpaturev
Stage: Not stated
Public float (as of ): $245M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
We expect to present data on potential long-term survivors in the fourth quarter of 2026.
Earlier SEC statements (3)
- · “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” · SEC filing
- · “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” · SEC filing
- · “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” · SEC filing
Period the company stated: fourth quarter of 2026
strategy during the fourth quarter of 2026.Details
Celcuity Inc. (CELC) · gedatolisib + darolutamide
Stage: Not stated
Public float (as of ): $457M (SEC filing) · Under $500M
Period the company stated: fourth quarter of 2026
We expect to provide updated clinical data and additional visibility into its mCRPC development strategy during the fourth quarter of 2026.
Period the company stated: Q4 2026
Q4 2026: QW updated dataDetails
Context Therapeutics Inc. (CNTX) · CTIM-76
Stage: Phase 1SEC filing · “Phase 1a”
Public float (as of ): $57M (SEC filing) · Under $500M
Period the company stated: Q4 2026
Q4 2026: QW updated data
ClinicalTrials.gov NCT06515713 · NCT stated in SEC filing
Period the company stated: Q4 2026
New Drug Application in Q4 2026.Details
CYTOKINETICS INC (CYTK) · aficamten
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $2.5B (SEC filing) · Over $2B
Period the company stated: Q4 2026
Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026.
Earlier SEC statements (1)
- · “Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026.” · SEC filing
Period the company stated: 4Q 2026
Treatment of Urticaria, in 4Q 2026Details
ENANTA PHARMACEUTICALS INC (ENTA) · EDP-978
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $110M (SEC filing) · Under $500M
Period the company stated: 4Q 2026
On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026
Earlier SEC statements (3)
- · “We expect to report topline data from this trial in the fourth quarter of 2026.” · SEC filing
- · “The Company expects to report topline data from the trial in the fourth quarter of 2026.” · SEC filing
- · “with topline Phase 1 data expected in the fourth quarter of 2026.” · SEC filing
Period the company stated: fourth quarter of 2026
data expected in the fourth quarter of 2026.Details
Edgewise Therapeutics, Inc. (EWTX) · sevasemten
Stage: Not stated
Public float (as of ): $1.2B (SEC filing) · $500M–$2B
Period the company stated: fourth quarter of 2026
top-line data expected in the fourth quarter of 2026.
Earlier SEC statements (2)
- · “top-line data expected in the fourth quarter of 2026.” · SEC filing
- · “The Company expects to report top-line data in the fourth quarter of 2026” · SEC filing
No program matches these filters. Ask for a company on the Watch page.
About this calendar
FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.
Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.
How this calendar is made
- Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
- Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
- Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
- Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
- Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
- Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
- Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
- Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
- Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
- “Wording changed” opens the earlier sentences, each with its date and filing.
- No forecast, price, score or signal. The calendar repeats what companies wrote.
Want an email when one of these changes? Get a free Watch.
Window ended
The company-stated period has ended. These records retain their wording and filing links.
1 programs as of
No ended windows match these filters.
Timing without a stated calendar date
These SEC statements retain an ambiguous period or an event trigger. No date or countdown is assigned.
3 records as of
No records match these filters. Choose All periods to view timing without a calendar date.
Results disclosed
An SEC resolution filing is held in these records. The original schedule, quote and source remain available.
47 programs as of
No disclosed records match these filters.